MIST — Milestone Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $70.04m
- $53.70m
Annual income statement for Milestone Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 15 | 5 | 1 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 50.7 | 58.1 | 64.6 | 62.1 | 42.1 |
| Operating Profit | -50.7 | -43.1 | -59.6 | -61.1 | -42.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -50 | -42.9 | -58.4 | -59.7 | -41.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -50 | -42.9 | -58.4 | -59.7 | -41.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -50 | -42.9 | -58.4 | -59.7 | -41.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -50 | -42.9 | -58.4 | -59.7 | -41.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.7 | -1.02 | -1.38 | -1.39 | -0.667 |